Nussbaum Ran 4
4 · UroGen Pharma Ltd. · Filed Feb 28, 2023
Insider Transaction Report
Form 4
Nussbaum Ran
Director
Transactions
- Exercise/Conversion
Ordinary Shares
2022-06-16$5.00/sh+2,211$11,055→ 1,437,169 total(indirect: Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd.) - Exercise/Conversion
Stock Option (right to buy)
2022-06-16−2,211→ 0 total(indirect: By Partnership)Exercise: $5.00From: 2015-09-01Exp: 2022-09-01→ Ordinary Shares (2,211 underlying)